Prelude Capital Management’s Sage Therapeutics SAGE Stock Holding History

Prelude Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-10,000	Closed	-$206K	–	1305
2023 Q3	$206K	Hold	10,000	–	–	0.01%	886
2023 Q2	$470K	Buy	+10,000	New	+$498K	0.03%	490

Other funds holding SAGE

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Prelude Capital Management's SAGE Position: Q3 2025 in Review

Prelude Capital Management sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 12,229 shares — an estimated $112K sold.

Prelude Capital Management first reported a position in SAGE in Q4 2016 and held it in 29 quarters. The position peaked at $983K in Q3 2022. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

Prelude Capital Management reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
Prelude Capital Management sold 12,229 Sage Therapeutics shares in Q3 2025, an estimated $112K.
Prelude Capital Management first reported a position in Sage Therapeutics in Q4 2016 and held it in 29 quarters.
Prelude Capital Management's Sage Therapeutics position peaked at $983K in Q3 2022.
5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.